Krenitsky Pharmaceuticals Inc. (KPI) is a privately held drug company in Chapel Hill, NC founded in 1995 after acquisition of Burroughs Wellcome by Glaxo Inc. The President and CEO of KPI, Thomas A. Krenitsky, was formerly the Vice President of Research at Burroughs Wellcome.
Who We Are:
What We Do:
Since its founding, KPI has been focused on the discovery and early development of drugs for treating diseases of the central nervous system. The company has been successful in the discovery of two drugs with significant commercial potential. KPI completed a comprehensive series of preclinical studies demonstrating the biological activity of these drugs, and both drugs were licensed out for clinical development. Recently, the licensee incurred financial difficulties and was forced to discontinue the clinical development program. All rights to both drugs reverted to KPI in 2013. KPI has relicensed TriRima to Cennerv Pharma and is presently seeking a new partner for further development and commercialization of KP544.
Candidates for Development
TriRima: A triple acting, selective and reversible inhibitor of monoamine oxidase-A (MAO-A).
Stage of development: The drug has completed Phase IIa.
Therapeutic use: Depression and related conditions such as anxiety and ADHD.